Analyst ratings, especially those initiating coverage, can significantly influence investor sentiment and stock prices. An Outperform rating suggests that Wolfe Research believes RAPT Therapeutics will outperform the market or its sector. The set price target of $39 indicates a positive outlook on the stock's future price movement, potentially leading to increased investor interest and a short-term price increase.